A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.
about
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signalsTargeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateTetraspanins as therapeutic targets in hematological malignancy: a concise reviewAdvances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-lifeAGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AMLThe CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia modelBroadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activityEffect of an anti-human Co-029/tspan8 mouse monoclonal antibody on tumor growth in a nude mouse model.The tetraspanin CD37 orchestrates the α(4)β(1) integrin-Akt signaling axis and supports long-lived plasma cell survival.Anti-CD37 antibodies for chronic lymphocytic leukemia.Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.Tetraspanin CD37 protects against the development of B cell lymphomaAssessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodiesDecitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blastsTargeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemiaA Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Targeting tetraspanins in cancer.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.Emerging therapies for refractory chronic lymphocytic leukemia.New targets for antibody therapy of pediatric B cell lymphomas.Promising therapies for the treatment of chronic lymphocytic leukemia.Emerging immunological drugs for chronic lymphocytic leukemia.Emerging antibody-drug conjugates for treating lymphoid malignancies.The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.Binding structures and energies of the human neonatal Fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations.Editorial: Membrane domains as new drug targets.Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.Generation and preclinical characterization of an antibody specific for SEMA4D.Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration.Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties.Alga-Made Anti-Hepatitis B Antibody Binds to Human Fcγ Receptors.Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Surrogate potency assays: Comparison of binding profiles complements dose response curves for unambiguous assessment of relative potencies.
P2860
Q24336378-9EF41630-B864-418A-B3D5-6D4CE38C240BQ26798062-4E4D383A-E901-4895-BBC2-C3D897CDD47EQ27002353-E2C5D2A9-F1EE-448A-8045-75860305766AQ28079016-25993CBB-AC2A-43BF-B26E-06FB52801ED0Q30403563-6F1DA497-1F7A-497B-B63A-1261D45748BCQ33875604-792775FA-4E42-406B-86DB-1749444CC7CEQ34204325-EB9A902B-2B50-474F-8DDA-A04EFE4670A9Q34211752-0D6B906B-E9E9-4030-A353-0433F866CE5EQ34311595-ED580B96-9C09-463C-AB93-4B72137A1AB5Q34405641-41036D3F-16CE-4EC9-B586-1940D909758DQ34440110-6B848E3E-B0A1-44AA-957C-413FB8852395Q34480345-AEF766F2-E001-4076-A86B-F640393CA4A9Q34509755-B58AA048-A7CD-468A-8406-70AA94803CF5Q34543066-05840911-57F1-4A56-B7CA-02BFB67B746FQ35154170-21AD7E20-1009-443A-843D-C1FF07EB12C8Q36989586-8406A929-7663-4805-9A4D-12F3F16EA96EQ37129235-E6FB804E-1B5E-4716-82DB-7B2F15397798Q37364355-ED89687B-2A85-4E13-A66D-D63ABFF8217CQ37524313-4094E01E-6FFF-4BD9-BA2B-6BB33629D0FFQ37609420-0BACF66A-7541-4CC6-814D-41072E7DB0E1Q37672472-E1DD19C7-CF2A-4F09-86BC-30E18E70A537Q38033584-4881790B-E4DA-4D8D-AB10-BE6C1E27E150Q38068494-3E62352B-7BE5-40FB-9BAF-225A55D0E07BQ38110472-FFF8D72E-610C-4B11-A085-9D84DD7D5742Q38207143-5A6959E7-D412-4BC0-A16B-19DA8B8643E1Q38242984-4DE0EA28-4DBE-45BD-A68D-D483649A5A3BQ38366441-804A2E72-B826-488B-9F40-FE4F20E386CFQ38543771-3A835D4D-4A4D-45B3-AD24-7BDE1E10191DQ38632313-C2E9C04C-EC89-49E5-9AE7-4F6F36C6F4D2Q38655388-4A3E3658-6A2E-4A9F-820B-B241CE89E30FQ39346415-77665493-0FD6-477E-8E43-A4198A38C043Q41513306-27F85D26-BEFF-4051-9BC0-4CD0F71E9653Q42355445-36F65E5F-70FD-48CB-A149-E9F810337B5CQ42393761-8A146F8B-FFA0-4804-8CFE-64317FD3CB64Q44501041-7235E0DD-B83A-4C0A-A38C-EAF257332544Q47265866-D6791353-6655-410E-A14F-496BFAB176DDQ47341896-ABC444AB-B0D7-4CC6-A474-AD29EC5965F5Q48541938-1FECD50D-4F81-4695-A7F8-41ED53B41C03Q49539698-0EEDF115-0B10-4D6C-BD67-7C87F7167CFAQ54988566-C78DE939-3DEE-467A-8F54-63A1DB486AF0
P2860
A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A novel Fc-engineered monoclon ...... atment of B-cell malignancies.
@ast
A novel Fc-engineered monoclon ...... atment of B-cell malignancies.
@en
type
label
A novel Fc-engineered monoclon ...... atment of B-cell malignancies.
@ast
A novel Fc-engineered monoclon ...... atment of B-cell malignancies.
@en
prefLabel
A novel Fc-engineered monoclon ...... atment of B-cell malignancies.
@ast
A novel Fc-engineered monoclon ...... atment of B-cell malignancies.
@en
P2093
P2860
P1433
P1476
A novel Fc-engineered monoclon ...... atment of B-cell malignancies.
@en
P2093
Alexander Jacobi
Elinborg Ostermann
Eric Borges
Günther R Adolf
Herbert Lamche
Karl-Heinz Heider
Kerstin Kiefer
Matthias Volden
Steffen Müller
P2860
P304
P356
10.1182/BLOOD-2011-04-351932
P407
P577
2011-07-27T00:00:00Z